Roche (RHHBY) gets exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed neurological targets for an initial payment of $42 million.
Terns Pharmaceuticals, Inc. (TERN) outperforms the industry year to date on encouraging pipeline progress of its oncology candidate.
Ligand Pharmaceuticals Incorporated ( NASDAQ:LGND ) shareholders should be happy to see the share price up 10% in the...